Page Title
Clinical Trial Finder
Ask About Participating in This Study
Anti-InfectiveClosed to Enrollment
Phase 2 study of inhaled nitric oxide in people with CF, protocol number Novoteris NO-CF-02EThe following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Anti-InfectiveClosed to Enrollment
Phase 2 study of inhaled nitric oxide in people with CF, protocol number Novoteris NO-CF-02E
This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug nitric oxide in adults with cystic fibrosis who are taking an inhaled antibiotic.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
35 to 85%
-
Number of Visits:
10
-
Length of Participation:
43 days
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More